Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$4.6 million.

  • Centessa Pharmaceuticals' Change in Account Payables rose 92.26% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 136.34%. This contributed to the annual value of -$4.6 million for FY2024, which is 68.44% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Change in Account Payables stood at -$4.6 million for FY2024, which was down 68.44% from -$2.7 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Change in Account Payables registered a high of $6.4 million during FY2022, and its lowest value of -$4.6 million during FY2024.
  • For the 3-year period, Centessa Pharmaceuticals' Change in Account Payables averaged around -$318,667, with its median value being -$2.7 million (2023).
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 8,583.67% in 2021, then crashed by 142.86% in 2023.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' Change in Account Payables stood at -$49,000 in 2020, then spiked by 8,583.67% to $4.2 million in 2021, then soared by 52.78% to $6.4 million in 2022, then tumbled by 142.86% to -$2.7 million in 2023, then slumped by 68.44% to -$4.6 million in 2024.